Tevogen (TVGN) Assets Average (2022 - 2026)
Tevogen Bio Holdings' (TVGN) quarterly Assets Average came in at $4.7 million in Q1 2026, up 23.48% YoY from $3.8 million in Q1 2025, and up 4.81% on a QoQ basis from $4.4 million in Q4 2025.
Tevogen (TVGN) Assets Average (2022 - 2026) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 5 years of Assets Average data on file, last reported at $4.7 million in Q1 2026.
- Quarterly Assets Average rose 23.48% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (up 23.48% YoY) and the FY2025 annual result came in at $3.9 million, down 12.52% from the prior year.
- Assets Average grew to $4.7 million in Q1 2026, from $4.4 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $355.8 million in Q4 2022 to a low of $3.3 million in Q2 2024.
- A 5-year average of $100.7 million and a median of $4.7 million in 2026 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2024 — Assets Average plunged 97.68% — and 2025, when it rose 25.0%.
- Tracing TVGN's Assets Average over 5 years: stood at $355.8 million in 2022, then tumbled by 95.52% to $16.0 million in 2023, then tumbled by 75.71% to $3.9 million in 2024, then advanced by 14.52% to $4.4 million in 2025, then advanced by 4.81% to $4.7 million in 2026.
- The last three Assets Average figures came in at $4.7 million (Q1 2026), $4.4 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 19.82 Bn |
| 10 | Tevogen | 25.39 Mn | 25.39 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.65 Mn |
| Dec 31, 2025 | 4.44 Mn |
| Sep 30, 2025 | 4.38 Mn |
| Jun 30, 2025 | 4.17 Mn |
| Mar 31, 2025 | 3.77 Mn |
| Dec 31, 2024 | 3.88 Mn |
| Sep 30, 2024 | 3.80 Mn |
| Jun 30, 2024 | 3.34 Mn |
| Mar 31, 2024 | 4.43 Mn |
| Dec 31, 2023 | 15.96 Mn |
| Sep 30, 2023 | 26.39 Mn |
| Jun 30, 2023 | 25.92 Mn |
| Mar 31, 2023 | 191.30 Mn |
| Dec 31, 2022 | 355.84 Mn |
| Sep 30, 2022 | 353.76 Mn |
| Jun 30, 2022 | 352.90 Mn |
| Mar 31, 2022 | 352.84 Mn |